

          -  Absolute lymphocyte count is less than 500 cells/mm

          -  Absolute neutrophil count is less than 1000 cells/mm

          -  Hemoglobin level is less than 8 g/dL

          -  Estimated GFR is less than 60 mL/min/1.73 m2

          -  ALT or AST is over 5 times the upper limit of normal

          -  Treatment with other JAK inhibitors, OAT3 inhibitors, biologic disease-modifying
             anti-rheumatic drugs (DMARDs), anti-IL-6 or anti-IL-6R antibodies, or potent
             immunosuppressants such as azathioprine. and cyclosporine concurrently or within the
             past 5 days. Note: recent or concurrent treatment with hydroxychloroquine or
             chloroquine is allowable, as these are 'non-biologic' DMARDs with potential antiviral
             activity.

          -  History of HIV infection and on active immunosuppressant therapy

          -  Current hematological or solid organ malignancy and on active immunosuppressant
             therapy

          -  Active tuberculosis (TB) infection or known or suspected systemic bacterial or fungal
             infection

          -  Pregnancy or breast feeding

          -  Known allergy to baricitinib

          -  In the opinion of the investigator, they are unlikely to survive for >48 hours from
             screening

          -  Any physical examination findings and/or history of any illness that, in the opinion
             of the investigator, might confound the results of the study or pose an additional
             risk to the patient by their participation in the study

        Additional Exclusion Criteria for Phase 2 only:

         Invasive oxygen supplementation, including mechanical ventilation and extracorporeal
        membrane oxygenation (ECMO)
      